Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/21/2008

Product sales increased 14% over third quarter 2007 to $201 million

SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2008. The Company reported total revenue of $218.4 million for the third quarter, including net product sales of $201.4 million, a 14% increase over the same period in 2007. Net loss for the quarter ended September 30, 2008 was $77.7 million, or $0.57 per share. Net loss per share, excluding an impairment loss on investments of $14.9 million, or $0.11 per share, was $0.46 per share.

"This quarter we reported strong product sales in the face of an increasingly challenging environment. Additionally we completed an exenatide once weekly product supply agreement with Lilly that strengthens our balance sheet and provides financial flexibility for the future," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We continue to manage the company towards sustainable, profitable growth by driving BYETTA and SYMLIN revenue, managing our expenses, and bringing exenatide once weekly to market."

Quarter ended September 30, 2008

Net product sales of $201.4 million for the third quarter include $179.9 million for BYETTA(R) (exenatide) injection and $21.5 million for SYMLIN(R) (pramlintide acetate) injection. This represents a 14% increase over net product sales of $177.4 million for the same period in 2007.

Revenues under collaborative agreements were $17.0 million for the quarter ended September 30, 2008, compared to $12.6 million for the same period in 2007. The increase reflects higher cost-sharing payments from Lilly for development expenses for BYETTA an
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Webcast Third Quarter Results
2. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
3. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
4. Amylin and Lilly Set Date and Time for Conference Call
5. Amylin Pharmaceuticals to Webcast Second Quarter Results
6. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
7. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
8. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
9. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
10. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
11. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Providerâ„¢ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, Inc. ... in connection with the acquisition of Durata Therapeutics, Inc. ... connection with the termination of PDL,s credit agreement with ... outstanding of $40 million, accrued interest, and prepayment and ... into a structured financing transaction with Durata in which ...
(Date:11/17/2014)... 17, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today the formation of a Medical Advisory Board ... Company as it advances the Phase 3 clinical ... of cutaneous T-cell lymphoma (CTCL), a rare class ...
(Date:11/15/2014)... 2014 The redesigned ActiGraph Link ... and sleep measurement platform with a rich feature ... with multiple new channels of sensor data captured ... with Bluetooth Smart technology, the ActiGraph Link supports ... uploads to ActiGraph’s cloud-based Study Admin platform, giving ...
Breaking Biology Technology:Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6ActiGraph Launches GT9X Link Activity Monitor 2
... ... ... ... , ...
... ... for different body types and shampoo bottles shaped to closely match the size of ... to redesign armor for troops in Afghanistan. , ... Madison, NJ, USA (PRWEB) February 24, 2010 -- Interactive exhibits make learning ...
... ... ... , ... , , , , ...
Cached Biology Technology:Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 2Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 3Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 4Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 5Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 6Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA) 7Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 2Science by the Seat of Their Pants - Museum Goers, Industry and the Military Take Pressure Off with Body Mapping 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... CITY, Nov. 5, 2014 – University of Utah engineers ... to help jet fuel produce electricity without needing to ... used to power portable electronics, off-grid power and sensors. ... today in the American Chemical Society journal ACS ... through a chemical reaction between a fuel and an ...
(Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... Information Network Studies (CWINS) at Worcester Polytechnic Institute (WPI) ... National Institute of Standards and Technology (NIST) to conduct ... around and through the human body. Led by Kaveh ... of CWINS, the research will help speed the development ...
... from the Robertson Foundation to create a state-of-the-art Translational ... cell therapy research and treatment programs for children and ... suffered at birth. In making the announcement, Victor J. ... Chief Executive Officer for Duke University Health System, said ...
... the world will be at the Marriott in Walnut ... Institute 5th Annual Genomics of Energy and Environment Meeting, ... clean energy generation and the environment. Keynote speeches will ... Joint BioEnergy Institute, Steve Pennell of Ceres Inc. on ...
Cached Biology News:WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 2WPI receives $1.2 million NIST award for pioneering study of wireless body area networks 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3DOE Joint Genome Institute 5th Annual Meeting on March 24-26, 2010 2